Combination therapy of glucocorticoids and proteasome inhibitors
Many disorders of the CNS change the functionality and integrity of the BBB. Glucocorticoids (GC) are being used successfully in the treatment of some disorders while their effects on others are questionable and the nature of the underlying molecular mechanisms is still a matter of debate. While glucocorticoids potently stabilize the blood brain barrier in neoplastic and inflammatory central nervous system disorders, they are however ineffective in other diseases of the CNS affecting BBB integrity.
Excessive proteasomal glucocorticoid receptor degradation has been identified as an important mechanism causing pharmacological insensitivity of brain microvascular endothelial cells to glucocorticoids in ischemic brain disorders like acute ischemic stroke. In vitro and in vivo, restoration of glucocorticoid sensitivity and effective edema reduction was achieved by inhibition of the proteasomal pathway by Bortezomib accompanied by treatment with a specific glucocorticoid.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
All latest news from the category: Technology Offerings
China claims new world record for strongest steady magnetic field
The hybrid magnet at the Steady High Magnetic Field Facility (SHMFF) in Hefei, China set a world record for the highest steady magnetic field by a working magnet when it…
Metaholographic platform that detects light exposure
During the COVID-19 pandemic last year, an incident occurred where vaccines exposed to room temperature had to be discarded. Biomedical substances, including vaccines, risk deterioration if not stored properly, so…
Similarity of hepatocytes from liver and from stem cells improved
Research with stem cells is becoming increasingly important, because stem cells can develop into any body cell – skin cells, nerve cells or organ cells such as liver cells, the…